User login
Pediatric Vaccines & Infectious Diseases: Fall 2018
Psoriasis & Psoriatic Arthritis - October 2018 Supplement
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
CME: Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes
Click here to read the digital edition of the supplement
This supplement is supported by an educational education grant from Celgene and Janssen Biotech, Inc.
Topics Include:
- Advances in diagnosis and prognosis
- Management of the newly diagnosed patient
- Treatment advances and current management strategies for relapsed/refractory patients
- Future treatment directions
About the Author
Thomas R. Chauncey, MD, PhD
Associate Professor of Medicine and Oncology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center
Director, Marrow Transplant Unit
VA Puget Sound Health Care System
Seattle, WA
Click here to read the digital edition of the supplement
Click here to read the digital edition of the supplement
This supplement is supported by an educational education grant from Celgene and Janssen Biotech, Inc.
Topics Include:
- Advances in diagnosis and prognosis
- Management of the newly diagnosed patient
- Treatment advances and current management strategies for relapsed/refractory patients
- Future treatment directions
About the Author
Thomas R. Chauncey, MD, PhD
Associate Professor of Medicine and Oncology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center
Director, Marrow Transplant Unit
VA Puget Sound Health Care System
Seattle, WA
Click here to read the digital edition of the supplement
Click here to read the digital edition of the supplement
This supplement is supported by an educational education grant from Celgene and Janssen Biotech, Inc.
Topics Include:
- Advances in diagnosis and prognosis
- Management of the newly diagnosed patient
- Treatment advances and current management strategies for relapsed/refractory patients
- Future treatment directions
About the Author
Thomas R. Chauncey, MD, PhD
Associate Professor of Medicine and Oncology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center
Director, Marrow Transplant Unit
VA Puget Sound Health Care System
Seattle, WA
Click here to read the digital edition of the supplement
Recommendations to Improve Asthma Outcomes: Work Group Call to Action
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Recommendations to Improve Asthma Outcomes: Work Group Call to Action
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Abstracts Presented at the 2018 AVAHO Annual Meeting (Digital Edition)
Acne and Rosacea - July 2018 Supplement
Acne & Rosacea is a supplement addressing quality of life, pathogenesis, and treatment of acne and rosacea, with an introduction from Julie C. Harper, M.D. "I am pleased to have so many thought-provoking articles to review on the subjects of acne and rosacea. Our understanding of hese common but life-changing conditions is improving, but there is still a long way to go."
Highlights include:
- New standard classification, pathophysiology of rosacea announced
- Clinicians persist in prescribing antibiotics for acne
- Rosacea tied to physical and psychological comorbidities
Click here to download this supplement.
Acne & Rosacea is a supplement addressing quality of life, pathogenesis, and treatment of acne and rosacea, with an introduction from Julie C. Harper, M.D. "I am pleased to have so many thought-provoking articles to review on the subjects of acne and rosacea. Our understanding of hese common but life-changing conditions is improving, but there is still a long way to go."
Highlights include:
- New standard classification, pathophysiology of rosacea announced
- Clinicians persist in prescribing antibiotics for acne
- Rosacea tied to physical and psychological comorbidities
Click here to download this supplement.
Acne & Rosacea is a supplement addressing quality of life, pathogenesis, and treatment of acne and rosacea, with an introduction from Julie C. Harper, M.D. "I am pleased to have so many thought-provoking articles to review on the subjects of acne and rosacea. Our understanding of hese common but life-changing conditions is improving, but there is still a long way to go."
Highlights include:
- New standard classification, pathophysiology of rosacea announced
- Clinicians persist in prescribing antibiotics for acne
- Rosacea tied to physical and psychological comorbidities
Click here to download this supplement.
Hot Topics in Primary Care 2018
Click here to read the full supplement.
This supplement includes 1.0 CME credits (scroll down for more information).
Articles include:
- Approach to the Identification and Differentiation of Migraine
- Long-term Treatment of Gout: New Opportunities for Improved Outcomes
- Individualizing Treatment with Statin Therapy
- Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
- From Randomized Controlled Trials to the Real World: Putting Evidence into Context
- Approaches to Increase Colorectal Cancer Screening Rates: Key Information for the Family Physician
This supplement offers the opportunity to earn a total of 1.0 CME credits.
Credit is awarded for successful completion of the online evaluations at the link below. This link may also be found within the supplement on the first page of the article.
- Long-term Treatment of Gout: New Opportunities for Improved Outcomes
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to www.pceconsortium.org/gout.
Click here to read the full supplement.
This supplement includes 1.0 CME credits (scroll down for more information).
Articles include:
- Approach to the Identification and Differentiation of Migraine
- Long-term Treatment of Gout: New Opportunities for Improved Outcomes
- Individualizing Treatment with Statin Therapy
- Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
- From Randomized Controlled Trials to the Real World: Putting Evidence into Context
- Approaches to Increase Colorectal Cancer Screening Rates: Key Information for the Family Physician
This supplement offers the opportunity to earn a total of 1.0 CME credits.
Credit is awarded for successful completion of the online evaluations at the link below. This link may also be found within the supplement on the first page of the article.
- Long-term Treatment of Gout: New Opportunities for Improved Outcomes
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to www.pceconsortium.org/gout.
Click here to read the full supplement.
This supplement includes 1.0 CME credits (scroll down for more information).
Articles include:
- Approach to the Identification and Differentiation of Migraine
- Long-term Treatment of Gout: New Opportunities for Improved Outcomes
- Individualizing Treatment with Statin Therapy
- Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
- From Randomized Controlled Trials to the Real World: Putting Evidence into Context
- Approaches to Increase Colorectal Cancer Screening Rates: Key Information for the Family Physician
This supplement offers the opportunity to earn a total of 1.0 CME credits.
Credit is awarded for successful completion of the online evaluations at the link below. This link may also be found within the supplement on the first page of the article.
- Long-term Treatment of Gout: New Opportunities for Improved Outcomes
- To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to www.pceconsortium.org/gout.
